Astria Therapeutics, Inc.
ATXSDelisted Jan 23, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001454789
Astria Therapeutics, Inc. was delisted on Jan 23, 2026; its insiders filed their last Form 4 on Jan 23, 2026; 141 institutions reported holding it in 13F filings for Q4 2025, worth $738.2M in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q2 2024
Institutional positions in Astria Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 100
- −2 vs. Q1 2024
- Shares held
- 55.6M
- −2.06M (−3.6%) vs. Q1 2024
- Total value
- $505.8M
- −$304.8M (−37.6%) vs. Q1 2024
- New holders
- 23
- 39 more added
- Sold out
- 25
- 27 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ATXS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 141 | $738.2M |
| Q3 2025 | 115 | $409.0M |
| Q2 2025 | 106 | $309.9M |
| Q1 2025 | 116 | $311.4M |
| Q4 2024 | 111 | $523.4M |
| Q3 2024 | 103 | $622.1M |
| Q2 2024 | 100 | $505.8M |
| Q1 2024 | 102 | $810.6M |
| Q4 2023 | 80 | $282.6M |
| Q3 2023 | 68 | $171.4M |
| Q2 2023 | 76 | $205.5M |
| Q1 2023 | 66 | $311.6M |
| Q4 2022 | 61 | $326.1M |
| Q3 2022 | 43 | $88.8M |
| Q2 2022 | 30 | $17.2M |
| Q1 2022 | 33 | $41.7M |
| Q4 2021 | 33 | $32.8M |
| Q3 2021 | 36 | $65.2M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Astria Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 0 | $0 | 0.00% | −1,300,000−100.0% | Sold out |
| Avidity Partners Management LP | 0 | $0 | 0.00% | −982,000−100.0% | Sold out |
| Artal Group S.A. | 0 | $0 | 0.00% | −884,214−100.0% | Sold out |
| Tri Locum Partners LP | 0 | $0 | 0.00% | −369,549−100.0% | Sold out |
| PFM Health Sciences, LP | 0 | $0 | 0.00% | −327,045−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −300,000−100.0% | Sold out |
| StemPoint Capital LP | 0 | $0 | 0.00% | −230,273−100.0% | Sold out |
| Altium Capital Management LP | 0 | $0 | 0.00% | −142,532−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −140,687−100.0% | Sold out |
| Toroso Investments, LLC | 0 | $0 | 0.00% | −118,200−100.0% | Sold out |
| Ghost Tree Capital, LLC | 0 | $0 | 0.00% | −115,000−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −70,241−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −30,313−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −25,453−100.0% | Sold out |
| American International Group, Inc. | 0 | $0 | 0.00% | −24,565−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −20,820−100.0% | Sold out |
| HAP Trading, LLC | 0 | $0 | 0.00% | −19,096−100.0% | Sold out |
| Belvedere Trading LLC | 0 | $0 | 0.00% | −16,036−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −13,507−100.0% | Sold out |
| Oppenheimer & Co Inc | 0 | $0 | 0.00% | −12,944−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −2,641−100.0% | Sold out |
| Quarry LP | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −396−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −84−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −7−100.0% | Sold out |